The recent approval of disease-modifying therapies for symptomatic Alzheimer's disease is a major advance for a condition with few therapeutic options. Anti-amyloid monoclonal antibodies have shown clinically meaningful benefits in slowing cognitive decline. Clinical trials in symptomatic Alzheimer's disease suggest th...
J. Graff-Radford, Leah Karliner, Deborah E. Barnes et al.· Lancet Neurology· 1 citation
SOMI’s risk profile in A4 was similar to prior findings in observational cohorts, and provides a low-cost, non-invasive enrichment tool for identifying individuals at risk for early cognitive decline in secondary prevention trials.
Priyanka Kumari, R. Lipton, A. Aschenbrenner et al.· The journal of prevention of...· 0 citations
Higher plasma p-tau217 levels were consistently associated with increased risk of clinical progression and accelerated cognitive decline, and support the potential of p-tau217 for prognostic model development, with direct implications for future trial design.
R. Buckley, D. Townsend, C. Birkenbihl et al.· Journal of the American Medi...· 3 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
